Fast Market Research

Report Published: "Macular Degeneration Therapeutics Market in Asia-Pacific to 2019 - Existing Angiogenics Retain Dominance Though High Unmet Need Remains"

Fast Market Research recommends "Macular Degeneration Therapeutics Market in Asia-Pacific to 2019 - Existing Angiogenics Retain Dominance Though High Unmet Need Remains" from GBI Research, now available

 
Repost This

Boston, MA -- (SBWIRE) -- 12/06/2013 -- GBI Research has released its research, "Macular Degeneration Therapeutics Market in Asia-Pacific to 2019 - Existing Angiogenics Retain Dominance Though High Unmet Need Remains", which provides in-depth insights into the macular degeneration market forecast until 2019 for the Asia-Pacific (APAC) region covering the four countries of Australia, China, India and Japan. It also covers disease epidemiology; treatment algorithms; treatment patterns; an in-depth analysis of clinical trials including failure rate analysis, pipeline analysis; and an analysis of deals relevant to macular degeneration. Apart from these the report also includes a heat map for the macular degeneration marketed products. GBI Research analysis shows that the APAC ophthalmology market for macular degeneration was valued at $675.7m in 2012. The market is expected to grow at a Compounded Annual Growth Rate (CAGR) of 6% for the forecast period and will reach $1,016m by 2019. Increase in the aging population and high annual cost of therapy of the marketed drugs are expected to drive the market valuations through 2019. However, the predominant off-label usage of Avastin for the treatment of the disease especially in developing countries like India and China act as a major barrier for growth of the market during the forecast period.

View Full Report Details and Table of Contents

Scope

- Disease overview along with treatment algorithms and treatment usage patterns
- Market size and forecast for the macular degeneration market in APAC from 2012 to 2019
- Major marketed products in the APAC along with a heat map
- In-depth analysis of pipeline along with clinical trial failure analysis
- Key drivers and restraints that have had a significant impact on the market
- Key licensing and co-development agreements in the macular degeneration market

Reasons to Get This Report

- Align your product portfolio to the markets with high growth potential
- Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
- Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the macular degeneration market
- Develop key strategic initiatives by understanding the key focus areas and leading companies
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Ophthalmology Therapeutics Market in Asia-Pacific to 2019 - High Unmet Need and Moderate Short Term Prospects Focus Attention on Early Stage Activity
- Inherited Orphan Blood Disorders Therapeutics Market to 2019 - Breakthrough Drugs Remain Elusive Against Backdrop of High Unmet Need
- Cytomegalovirus (CMV) Infections - Pipeline Assessment and Market Forecasts to 2019
- Pain Management Therapeutics Market to 2019 - Impact of Patent Expiries Offset by Demand for Neuropathic and Rheumatoid Pain Medications and Strong Pipeline
- Women's Health Therapeutics Market to 2018 - Unmet Need for Safe and Effective Treatments due to Unfavorable Risk/Benefit Profile Associated with Hormone Replacement Therapy
- Macular Degeneration - Pipeline Review, H2 2013
- Macular Degeneration - Pipeline Review, H1 2013
- Amyotrophic Lateral Sclerosis - Analysis and Market Forecasts to 2019
- MediPoint: Drug-Eluting Balloons - EU Analysis and Market Forecasts
- Age Related Macular Degeneration - Pipeline Review, H1 2013